Company news

Cabaletta Bio, Inc. news in 2020

Cabaletta Bio, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris

December 7, 2020

Cabaletta Bio to Participate in Upcoming December Investor Conferences

November 22, 2020

Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update

November 9, 2020

Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris

August 24, 2020

Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies

July 6, 2020

Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania

May 27, 2020

Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform

May 17, 2020

Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

May 5, 2020

Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

March 29, 2020

FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris

January 28, 2020

Decks in 2020